Gary S. Hogge is VP at Lineage Cell Therapeutics, Inc. (LCTX). They have made 1 open-market trade across 1 company since 2021, most recently 2023-02-11.
CIK 0001771711
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| LCTX | 13,020 | $13K |
Shares reported on the most recent Form 4, priced at the 2023-02-14 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| LCTX | SELL | 2021-12-28 | 2021-12-30 | $2.45 | $2.6M | -17.2% | -35.2% | -38.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.